These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Fischetti VA Int J Med Microbiol; 2010 Aug; 300(6):357-62. PubMed ID: 20452280 [TBL] [Abstract][Full Text] [Related]
4. Lysin Therapy for Staphylococcus aureus and Other Bacterial Pathogens. Fischetti VA Curr Top Microbiol Immunol; 2017; 409():529-540. PubMed ID: 26728063 [TBL] [Abstract][Full Text] [Related]
5. Exploiting what phage have evolved to control gram-positive pathogens. Fischetti VA Bacteriophage; 2011 Jul; 1(4):188-194. PubMed ID: 23050211 [TBL] [Abstract][Full Text] [Related]
6. Lysins: the arrival of pathogen-directed anti-infectives. Pastagia M; Schuch R; Fischetti VA; Huang DB J Med Microbiol; 2013 Oct; 62(Pt 10):1506-1516. PubMed ID: 23813275 [TBL] [Abstract][Full Text] [Related]
7. Recombinant bacteriophage lysins as antibacterials. Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123 [TBL] [Abstract][Full Text] [Related]
8. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Vázquez R; García E; García P Front Immunol; 2018; 9():2252. PubMed ID: 30459750 [TBL] [Abstract][Full Text] [Related]
9. Bacteriophages that infect Gram-negative bacteria as source of signal-arrest-release motif lysins. Gontijo MTP; Vidigal PMP; Lopez MES; Brocchi M Res Microbiol; 2021 Mar; 172(2):103794. PubMed ID: 33347948 [TBL] [Abstract][Full Text] [Related]
10. Phage-derived lysins as therapeutic agents against multidrug-resistant Enterococcus faecalis. Gu J; Xi H; Cheng M; Han W Future Microbiol; 2018 Mar; 13():275-278. PubMed ID: 29441802 [No Abstract] [Full Text] [Related]
11. Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus. Ma Q; Guo Z; Gao C; Zhu R; Wang S; Yu L; Qin W; Xia X; Gu J; Yan G; Lei L Antonie Van Leeuwenhoek; 2017 Mar; 110(3):347-355. PubMed ID: 27943012 [TBL] [Abstract][Full Text] [Related]
12. A genetic screen to identify bacteriophage lysins. Schuch R; Fischetti VA; Nelson DC Methods Mol Biol; 2009; 502():307-19. PubMed ID: 19082564 [TBL] [Abstract][Full Text] [Related]
13. LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity. Kim S; Jin JS; Choi YJ; Kim J Viruses; 2020 Nov; 12(11):. PubMed ID: 33238548 [TBL] [Abstract][Full Text] [Related]
14. Bacteriophage endolysins as a novel class of antibacterial agents. Borysowski J; Weber-Dabrowska B; Górski A Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432 [TBL] [Abstract][Full Text] [Related]
15. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Hermoso JA; García JL; García P Curr Opin Microbiol; 2007 Oct; 10(5):461-72. PubMed ID: 17904412 [TBL] [Abstract][Full Text] [Related]
16. The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region. Wang S; Gu J; Lv M; Guo Z; Yan G; Yu L; Du C; Feng X; Han W; Sun C; Lei L J Microbiol; 2017 May; 55(5):403-408. PubMed ID: 28124780 [TBL] [Abstract][Full Text] [Related]
17. Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis. Lukacik P; Barnard TJ; Buchanan SK Biochem Soc Trans; 2012 Dec; 40(6):1503-6. PubMed ID: 23176506 [TBL] [Abstract][Full Text] [Related]
18. Novel method to control pathogenic bacteria on human mucous membranes. Fischetti VA Ann N Y Acad Sci; 2003 Apr; 987():207-14. PubMed ID: 12727641 [TBL] [Abstract][Full Text] [Related]
19. EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis. Proença D; Leandro C; Garcia M; Pimentel M; São-José C Appl Microbiol Biotechnol; 2015 Jun; 99(12):5137-49. PubMed ID: 25728445 [TBL] [Abstract][Full Text] [Related]
20. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy. Oliveira H; São-José C; Azeredo J Viruses; 2018 May; 10(6):. PubMed ID: 29844287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]